Literature DB >> 26185608

Leukocyte Derived Chemotaxin 2 (ALECT2) Amyloidosis.

Uday Kulkarni1, Anna Valson2, Anila Korula3, Vikram Mathews1.   

Abstract

We describe the first case from India of ALECT2 amyloidosis. An adult Punjabi male presented with progressive renal dysfunction and non-nephrotic range proteinuria. Serum protein electrophoresis and immunofixation were normal, with mildly elevated serum free light chain ratio. A renal biopsy confirmed the presence of amyloid. Immunohistochemistry was negative for monoclonal light chains. Proteomic analysis confirmed the presence of ALECT2 amyloid. The present case highlights the need for confirmatory testing for typing of amyloid.

Entities:  

Year:  2015        PMID： 26185608      PMCID： PMC4500494          DOI： 10.4084/MJHID.2015.043

Source DB:  PubMed          Journal:  Mediterr J Hematol Infect Dis        ISSN： 2035-3006            Impact factor:   2.576


  7 in total

Review 1.  Leukocyte Cell-Derived Chemotaxin 2-Associated Amyloidosis: A Recently Recognized Disease with Distinct Clinicopathologic Characteristics.

Authors:  Samih H Nasr; Ahmet Dogan; Christopher P Larsen
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-14       Impact factor: 8.237

2.  Leukocyte chemotactic factor 2: A novel renal amyloid protein.

Authors:  Merrill D Benson; Sam James; Katherine Scott; Juris J Liepnieks; Barbara Kluve-Beckerman
Journal:  Kidney Int       Date:  2008-04-30       Impact factor: 10.612

3.  Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis.

Authors:  Samar M Said; Sanjeev Sethi; Anthony M Valeri; Anthony Chang; Cynthia C Nast; Leslie Krahl; Peter Molloy; Marc Barry; Mary E Fidler; Lynn D Cornell; Nelson Leung; Julie A Vrana; Jason D Theis; Ahmet Dogan; Samih H Nasr
Journal:  Kidney Int       Date:  2014-01-22       Impact factor: 10.612

4.  Alect2 amyloidosis: primum non nocere (first, do no harm).

Authors:  Maria M Picken
Journal:  Kidney Int       Date:  2014-08       Impact factor: 10.612

5.  Clinical, morphologic, and genetic features of renal leukocyte chemotactic factor 2 amyloidosis.

Authors:  Christopher P Larsen; Robert J Kossmann; Marjorie L Beggs; Alan Solomon; Patrick D Walker
Journal:  Kidney Int       Date:  2014-02-12       Impact factor: 10.612

6.  Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients.

Authors:  Stefan O Schönland; Ute Hegenbart; Tilmann Bochtler; Anja Mangatter; Marion Hansberg; Anthony D Ho; Peter Lohse; Christoph Röcken
Journal:  Blood       Date:  2011-11-21       Impact factor: 22.113

7.  Prevalence and morphology of leukocyte chemotactic factor 2-associated amyloid in renal biopsies.

Authors:  Christopher P Larsen; Patrick D Walker; Deborah T Weiss; Alan Solomon
Journal:  Kidney Int       Date:  2010-02-24       Impact factor: 10.612
  7 in total
  5 in total

1.  Amyloidosis: The Newer Discovered ALECT2 Associated with der7q add(7).

Authors:  Amrita Chakrabarti; Priyanka Samal; Joydeep Chakrabartty
Journal:  J Clin Diagn Res       Date:  2016-09-01

2.  Bystander LECT2 amyloidosis in tumor nephrectomy.

Authors:  A J Gallan; B Bhasin-Chhabra; D Kilari; S Johnson; A D'Souza
Journal:  CEN Case Rep       Date:  2022-08-20

3.  Leukocyte chemotactic factor 2 amyloidosis (ALECT2) is a common form of renal amyloidosis among Egyptians.

Authors:  Christopher P Larsen; Wesam Ismail; Paul J Kurtin; Julie A Vrana; Surendra Dasari; Samih H Nasr
Journal:  Mod Pathol       Date:  2016-02-12       Impact factor: 7.842

4.  Leukocyte Cell-Derived Chemotaxin 2-Associated Renal Amyloidosis: A Case Report.

Authors:  Gagandeep Kaur; Babitha Bijin; Kamron Saleem; Benjamin Sarsah; Bijin Thajudeen
Journal:  Case Rep Nephrol Dial       Date:  2017-12-11

5.  Renal amyloidogenic leukocyte chemotactic factor 2 combined with IgA nephropathy: A case report.

Authors:  Hongzhao Xu; Ye Jia; Xueyao Wang; Hui Wang; Jinyu Yu; Wu Hao
Journal:  Medicine (Baltimore)       Date:  2022-07-22       Impact factor: 1.817
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.